29 сентября, 17:50

Abbott's Ellipse ICD Receives FDA Approval for MRI Scans

Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.

29 сентября, 16:16

Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm

Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.

28 сентября, 17:34

Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI

Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.

28 сентября, 16:18

Mazor Robotics Gets CE Mark for Surgical Assurance Platform

Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.

27 сентября, 16:57

Mazor Robotics' CE Mark for Mazor X Platform to Drive Orders

Mazor Robotics and Medtronic will now be able to market and sell the Mazor X Surgical Assurance Platform in countries that recognize the CE Mark.

26 сентября, 23:23

Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

22 сентября, 16:40

Medtronic Advances in Pain Therapy With U.S. Intellis Launch

We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.

22 сентября, 14:56

Medtronic (MDT) Down 2.7% Since Earnings Report: Can It Rebound?

Medtronic (MDT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
15 сентября, 18:05

4 Momentum Stocks to Pick Despite MedTech Policy Debacle

Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.

13 сентября, 18:24

Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm

Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

13 сентября, 17:02

Medtronic Launches StealthStation Technology, Expands in ENT

Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.

12 сентября, 17:23

Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag

Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.

Выбор редакции
11 сентября, 13:48

Medtronic recalls diabetes infusion sets

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

28 июля, 17:57

United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top

United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.

21 июля, 13:53

Что читают в Гарварде? 11 обязательных книг

В современном мире хорошее образование играет очень большую роль. Все выдающиеся предприниматели нашего времени получили отличное образование в лучших вузах мира.

21 июля, 13:53

Что читают в Гарварде? 11 обязательных книг

В современном мире хорошее образование играет очень большую роль. Все выдающиеся предприниматели нашего времени получили отличное образование в лучших вузах мира.

21 июля, 06:18

Word on Wall Street: Medtronic's Diabetes Segment Generating Excitement

Medtronic is a pure-play medical device company. As a quick overview, Medtronic is split up into four segments: the Cardiac and Vascular Group (CVG), the Minimally Invasive Group (MITG), the Restorative Therapies Group (RTG), and the Diabetes Group (DG). For those who are unfamiliar, let’s first talk about diabetes and survey the available treatments.

18 июля, 16:30

Medtronic InterStim System Shows Five-Year Positive Results

Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.

Выбор редакции